Tasly Pharmaceutical Group Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Tasly Pharmaceutical Group (SHSE:600535) Second Quarter 2024 Results
Key Financial Results
- Revenue: CN¥2.32b (flat on 2Q 2023).
- Net income: CN¥367.1m (down 17% from 2Q 2023).
- Profit margin: 16% (down from 19% in 2Q 2023).
- EPS: CN¥0.25 (down from CN¥0.29 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tasly Pharmaceutical Group EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 8.6%. Earnings per share (EPS) exceeded analyst estimates by 14%.
Looking ahead, revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.
Performance of the Chinese Pharmaceuticals industry.
The company's shares are down 3.4% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Tasly Pharmaceutical Group has 2 warning signs we think you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Tasly Pharmaceutical Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:600535
Tasly Pharmaceutical Group
Engages in the pharmaceutical business in China and internationally.
Flawless balance sheet, undervalued and pays a dividend.